Global Enzyme Linked Immunosorbent Assay Overview
Enzyme linked immunosorbent assay (elisa) Market was valued at US$ 2.7 Billion in 2024 and is projected to grow at a CAGR of 9.30%to reach US$ 6 Billion by 2034.
Enzyme linked Immunosorbent Assay (ELISA) is an immunological assay commonly used for measuring antibodies, antigens, proteins and glycoproteins in biological samples. ELISA is majorly used for diagnosis of HIV infection, pregnancy tests, and measurement of cytokines or soluble receptors in cell supernatant or serum. ELISA assays are conducted in 96 well plates, which allow multiple samples to be measured in a single experiment. These plates are absorbent to antibody or antigen. Each ELISA measures a specific antigen and kits for a variety of antigens are widely available. The assay is versatile, as it can measure different combination of reagent allowing passive immobilization of reagents to solid phase and easy separation of bound/unbound reactants using washing steps.
Rising product development activities for ELISA kits has become the major factor in target market growth. For instance, May 2021, DRDO (Defence Research and Development Organization) developed indigenous antibody detection based kit “DIPCOVAN” which offers faster turn-around time with 75 minutes to carry out test without any cross reactivity with other type of diseases. Further, rising prevalence of infectious diseases is also expected to drive the Enzyme Linked Immunosorbent Assay Market.
For More Report Details, Download Free Sample PDF
Global Enzyme Linked Immunosorbent Assay Drivers & Restraints
Increasing adoption of advanced diagnostic procedures and research and development in the field of immunoassay and diagnostics is propelling demand for ELISA assay in various medical fields, owing to various advantages provided by it such as examining of multiple samples with high capacity and sensitivity, which provides range of detection for critical assays. Furthermore, key players in the market are focused on developing advanced and novel products to meet increasing diagnostics demand for healthcare industry, which is driving growth of the market. Moreover, increasing incidence of infectious diseases and cancer is fueling growth of the Enzyme Linked Immunosorbent Assay (ELISA) market.
Rising prevalence of infectious diseases
Rising prevalence of infectious diseases such as dengue, HIV, malaria, hepatitis, influenza and others is significantly contributed in Enzyme Linked Immunosorbent Assay (ELISA) market growth. For instance, according to CDC (Centers for Disease Control and Prevention), at the end of year 2019, it was estimated that around 1,189,700 people aged 13 and older diagnosed with HIV (Human Immunodeficiency Virus) in United States.
Restrains of Enzyme Linked Immunosorbent Assay (ELISA) market:
Nonspecific results due to cross-reactivity with secondary antibody and time required for completion of procedure are some of the factors restraining market growth. Further, stringent government regulations for approval of ELISA kits and lack of skilled professionals for handling ELISA equipment has hampered Enzyme Linked Immunosorbent Assay (ELISA) market growth.
Global Enzyme Linked Immunosorbent Assay Segmentations & Regional Insights
The Enzyme Linked Immunosorbent Assay (ELISA) market is segmented based on Method, Application, Technology and Region.
On the basis of Method, the Enzyme Linked Immunosorbent Assay (ELISA) market is segmented into Direct ELISA, Indirect ELISA, Sandwich ELISA and Competitive ELISA. On the basis of Application, the target market is segmented into Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry, and Transplantation. On the basis of Technology, the target market is segmented into Chemiluminescent, Colorimetric, and Fluorescent.
Regional Insights:
On the basis of region the Enzyme Linked Immunosorbent Assay (ELISA) Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to increasing presence of biopharmaceutical industries with increasing demand of precision medicine. Further, rising prevalence of chronic diseases, rising geriatric population, robust healthcare infrastructure, technological development in medical devices is anticipated to increase demand for Enzyme Linked Immunosorbent Assay (ELISA) in the region.
For instance, in 2020, according to CDC (Centers for Disease Control and Prevention), about 697,000 people in United States died from heart disease.
Attribute |
Details |
Base year for estimation |
2023 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Market Segmentation |
By Method - Direct ELISA, Indirect ELISA, Sandwich ELISA and Competitive ELISA By Application - Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry, and Transplantation By Technology - Chemiluminescent, Colorimetric, and Fluorescent
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Enzyme Linked Immunosorbent Assay (ELISA) Market report based on Method, Application, Technology and Region.
Enzyme Linked Immunosorbent Assay (ELISA) Market, By Method:
- Direct ELISA
- Indirect ELISA
- Sandwich ELISA
- Competitive ELISA
Enzyme Linked Immunosorbent Assay (ELISA) Market, By Application:
- Vaccine Development
- Immunology
- Diagnostics
- Toxicology
- Drug Monitoring & Pharmaceutical Industry
- Transplantation
Enzyme Linked Immunosorbent Assay (ELISA) Market, By Technology:
- Chemiluminescent
- Colorimetric
- Fluorescent
Enzyme Linked Immunosorbent Assay (ELISA) Market, By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global Enzyme Linked Immunosorbent Assay Competitive Landscape & Key Players
The key players operating the Enzyme Linked Immunosorbent Assay (ELISA) Market includes, Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd., and others.
Global Enzyme Linked Immunosorbent Assay Recent News
Recent Development:
- In February 2023, Charles River launched Novel IgY-based ELISA kit for detection and quantification of residual host cell protein in CHO-based biotherapies. Newly launched HCP ELISA kit leverages avian IgY antibodies as primary detection technology.
- In March 2022, Promega launched new Lumit Immunoassays for ELISA users which can quantitatively detect released cytokines from cell culture samples within 70 minutes. Newly launched assay are scalable for use in basic research and high-throughput screening used for drug discovery and development.
Global Enzyme Linked Immunosorbent Assay Company Profile
- Bio-Rad Laboratories, Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Enzo Life Sciences, Inc.
- Thermo Fisher Scientific, Inc.
- Biomerieux S.A.
- Alpco
- BioLegand, Inc.
- Zeus Scientific, Inc.
- Shenzhen YHLO Biotech Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section
Global Enzyme Linked Immunosorbent Assay Highlights
FAQs
Enzyme Linked Immunosorbent Assay (ELISA) market is segmented on the basis of method, application, technology, and geography.
key players in the market are focused on developing advanced and novel products to meet increasing diagnostics demand for healthcare industry, which is driving growth of the market.
The North America dominates the cell culture market owing to increasing presence of biopharmaceutical industries with increasing demand of precision medicine.
Non-specific results due to cross-reactivity with secondary antibody and time required for completion of procedure are some of the factors restraining market growth.